Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.1
(-2.36%)
SEK 3.1
(-2.36%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -3.24 SEK | 16.92% |
| 2022 | -3.90 SEK | -2.09% |
| 2021 | -3.82 SEK | -1.6% |
| 2020 | -3.76 SEK | -105.46% |
| 2019 | -1.83 SEK | 15.28% |
| 2018 | -2.16 SEK | -100.0% |
| 2017 | -1.08 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.49 SEK | -58.06% |
| 2024 Q2 | -0.27 SEK | 44.9% |
| 2023 Q1 | -1.07 SEK | 32.7% |
| 2023 Q4 | -0.31 SEK | 50.79% |
| 2023 FY | - SEK | 42.56% |
| 2023 Q2 | -1.19 SEK | -11.21% |
| 2023 Q3 | -0.63 SEK | 47.06% |
| 2022 Q2 | -0.68 SEK | 19.05% |
| 2022 Q1 | -0.84 SEK | 25.0% |
| 2022 FY | - SEK | -2.09% |
| 2022 Q3 | -0.77 SEK | -13.24% |
| 2022 Q4 | -1.59 SEK | -106.49% |
| 2021 Q1 | -1.00 SEK | 20.0% |
| 2021 FY | - SEK | -1.6% |
| 2021 Q2 | -1.01 SEK | -1.0% |
| 2021 Q3 | -0.82 SEK | 18.81% |
| 2021 Q4 | -1.12 SEK | -36.59% |
| 2020 FY | - SEK | -105.46% |
| 2020 Q2 | -1.31 SEK | -84.51% |
| 2020 Q4 | -1.25 SEK | -145.1% |
| 2020 Q3 | -0.51 SEK | 61.07% |
| 2020 Q1 | -0.71 SEK | 38.79% |
| 2019 Q2 | -0.62 SEK | 8.82% |
| 2019 Q1 | -0.68 SEK | -112.5% |
| 2019 FY | - SEK | 15.28% |
| 2019 Q4 | -1.16 SEK | -114.81% |
| 2019 Q3 | -0.54 SEK | 12.9% |
| 2018 Q1 | -0.20 SEK | 51.22% |
| 2018 FY | - SEK | -100.0% |
| 2018 Q2 | -0.35 SEK | -75.0% |
| 2018 Q3 | -0.26 SEK | 25.71% |
| 2018 Q4 | -0.32 SEK | -23.08% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | -0.41 SEK | 24.07% |
| 2017 Q3 | -0.54 SEK | 0.0% |